No Detail Found!

Impact of lifestyle modification on nonalcoholic fatty liver with prediabetes and type 2 diabetes

Author(s)
Dharma Lindarto Department of Internal Medicine, Faculty of Medicine,Universitas Sumatera Utara, Medan,Indonesia
Darmadi Darmadi Department of Internal Medicine, Faculty of Medicine,Universitas Sumatera Utara, Medan,Indonesia
Brama Ihsan Sazli Department of Internal Medicine, Faculty of Medicine,Universitas Sumatera Utara, Medan,Indonesia
Abstract
Prediabetes is characterized by impaired glucose uptake and insulin sensitivity in the muscle, as well as a significant risk of developing diabetes, chronic renal disease, cardiovascular disease, and death. A definite bidirectional connection exists between pre-diabetes, diabetes, and NAFLD. The presence of NAFLD is associated with the subsequent development of newonset type 2 diabetes (T2DM). There was a 6-fold rise in new-onset diabetes in people whose fatty liver severity progressed from mild to moderate or severe over 5 years, and a decrease in T2DM incidence comparable to that in those without steatosis. Insulin resistance is a common pathophysiological mechanism across metabolic illnesses, including prediabetes, diabetes, and NAFLD. As a result, better names for metabolically linked metabolic fatty liver disease have been considered. Lifestyle is the cornerstone of treatment for patients with prediabetes, T2DM, and NAFLD. Several significant randomized controlled trials show that acustomized low-calorie meal plan and behavioral change are highly effective in preventing or delaying prediabetes, type 2 diabetes, and improving other cardiometabolic markers (such as blood pressure,lipids, and inflammation). Several drugs already approved for the treatment of prediabetes and diabetesare beneficial for NAFLD/NASH
Publication Details
Page(s) 1-5
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 49, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
Diabetes Mellitus, prediabetes, Non-Alcoholic Fatty Liver Disease, NAFLD.
References
Echouffo-Tcheugui JB,Selvin E.,Prediabetes E. . .The Epidemiological Evidence. Annu Rev Public Health. 2021 Apr, 1(1) : 59-77.
Ciardullo S,Monti T,Perseghin G . .High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes. Diabetes Care. 2021 Feb, 1(2) : 519-25.
Lazarus J V.,Mark HE,Anstee QM,Arab JP,Batterham RL,Castera L . .Advancing the global public health agenda for NAFLD: a consensus statement. 2022 Jan, 27(1) : 60-78.
Song K,Park G,Lee HS,Lee M,Lee HI,Ahn J . .Trends in Prediabetes and Non-Alcoholic Fatty Liver Disease Associated with Abdominal Obesity among Korean Children and Adolescents: Based on the Korea National Health and Nutrition Examination Survey between 2009 and 2018. 2022 Mar, 2(3) : 584.
Song M,Zhao X,Shang Y. .2020 .The impact of low-carbon city construction on ecological efficiency: Empirical evidence from quasi-natural experiments. Resour Conserv Recycl, 157 : 104777.
Mendez-Sanchez N,Cruz-Ramon V,Ramirez-Perez O,Hwang J,Barranco-Fragoso B,Cordova-Gallardo J .2034 .New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis. Int J Mol Sci. 2018 Jul, 13(7) : .
Apostolopoulou M,Gordillo R,Koliaki C,Gancheva S,Jelenik T,De Filippo E . .Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis. Diabetes Care. 2018 Jun, 1(6) : 1235-43.
Morgantini C,Jager J,Li X,Levi L,Azzimato V,Sulen A . .Liver macrophages regulate systemic metabolism through non-inflammatory factors. 2019 Mar, 25(4) : 445-59.
Coats BR,Schoenfelt KQ,Barbosa-Lorenzi VC,Peris E,Cui C,Hoffman A . .Metabolically Activated Adipose Tissue Macrophages Perform Detrimental and Beneficial Functions during Diet-Induced Obesity. Cell Rep, 20(13) : 3149-61.
Boutari C,Mantzoros CS . .Adiponectin and leptin in the diagnosis and therapy of NAFLD. , 103 : 154028.
Campo L,Eiseler S,Apfel T,Pyrsopoulos N. . .Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. 2019 Mar, 28(1) : 1-5.
Hong S hyeon . .Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences. Int J Mol Sci. 2020 Jan, 13(2) : 494.
Francque SM,Marchesini G,Kautz A,Walmsley M,Dorner R,Lazarus JV . .Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep, 3(5) : 100322.
Ryan MC,Itsiopoulos C,Thodis T,Ward G,Trost N,Hofferberth S .2013 .The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol, 59(1) : 138-43.
WC Knowler SFRHCCHHAB .2009 .-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. The Lancet, 374(9702) : 1677-86.
Louheranta J,Mannelin A,Rastas M,Salminen M,Eriksson V,J V . .. Diabetes Care. 2003 Dec, 1(12) : 3230-6.
Srivastava RAK .2018 .Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity. J Diabetes Metab Disord, 17(2) : 381-91.
Li W,Zhu X,Song Y,Fan L,Wu L,Kabagambe EK .2018 .Intakes of magneisum, calcium and risk of fatty liver disease and prediabetes. Public Health Nutr, 21(11) : 2088-95.
Colletta C,Colletta A,Placentino G .2020 .Lifestyle and silymarin: A fight against liver damage in NAFLD associated - prediabetic disease. J Diabetes Metab Disord, 19(2) : 883-94.
ElSayed NA,Aleppo G,Aroda VR,Bannuru RR,Brown FM,Bruemmer D . .9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes2023. Diabetes Care. 2023 Jan, 1(Supplement) : S140-57.
Bhat A .2015 .Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol, 7(12) : 1652.
Cusi K,Orsak B,Bril F,Lomonaco R,Hecht J,OrtizLopez C . .Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. 2016 Sep, 6(5) : 305.
Thondam SK,Cuthbertson DJ,Wilding JPH .2020 .The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD). Peptides (NY), 125 : 170208.
Mazidi M,Katsiki N,Mikhailidis DP,Banach M. . .Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. 2019 Oct, 3(7) : 633-9.
Bomhof MR,Parnell JA,Ramay HR,Crotty P,Rioux KP,Probert CS . .Histological improvement of nonalcoholic steatohepatitis with a prebiotic: a pilot clinical trial. 2019 Jun, 19(4) : 1735-45.
Kato H,Nagai Y,Ohta A,Tenjin A,Nakamura Y,Tsukiyama H .2015 .Effect of sitagliptin on intrahepatic lipid content and body fat in patients with type 2 diabetes. Diabetes Res Clin Pract, 109(1) : 199-205.
Cui J,Philo L,Nguyen P,Hofflich H,Hernandez C,Bettencourt R .2016 .Sitagliptin vs. placebo for nonalcoholic fatty liver disease: A randomized controlled trial. J Hepatol, 65(2) : 369-76.
Macauley M,Hollingsworth KG,Smith FE,Thelwall PE,Al-Mrabeh A,Schweizer A .2015 .. Effect of Vildagliptin on Hepatic Steatosis. J Clin Endocrinol Metab, 100(4) : 1578-85.
Hussain M,Majeed Babar MZ,Hussain MS,Akhtar L . .Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease. Pak J Med Sci. 2016 Nov, 15(6) : .
Mazzotti A,Caletti MT,Marchignoli F,Forlani G,Marchesini G.,Disease Liver .2017 .Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? Digestive. , 49(3) : 235-40.
Gunanti IR,Marks GC,Al-Mamun A,Long KZ .2014 .Low Serum Concentrations of Carotenoids and Vitamin E Are Associated with High Adiposity in Mexican-American Children. J Nutr, 144(4) : 489-95.
Khaire A,Rathod R,Kale A,Joshi S. Vitamin . .B12 and omega-3 fatty acids together regulate lipid metabolism in Wistar rats. Prostaglandins Leukot Essent Fatty Acids, 99 : 7-17.
Wang Y,Ausman LM,Greenberg AS,Russell RM,Wang XD . .Dietary lycopene and tomato extract supplementations inhibit nonalcoholic steatohepatitispromoted hepatocarcinogenesis in rats. 2010 Apr, 15(8) : 1788-96.
0

Citations

0

Downloads

38

Views